GlassScriptPhysician profile
Mark J Savant
NPI 1386732352
$3,608.39
in general payments reported to CMS, 2019-2025
29 companies · $790 in 2025
The $790 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.06 · 2020: $23.13 · 2021: $51.45 · 2022: $417 · 2023: $909 · 2024: $1,401 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,100.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $519.24 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $454.63 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $394.44 | 2023-2025 | |
| Abbvie INC. | $391.63 | 2022-2025 | Viberzi, Linzess, Qulipta |
| Amgen INC. | $207.65 | 2020-2024 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $199.42 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $143.82 | 2025 | Yeztugo |
| Astellas Pharma US INC | $142.38 | 2022-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $123.04 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $116.57 | 2023-2024 | Rexulti |
| Avita Medical Americas, LLC | $103.79 | 2024 | |
| Viiv Healthcare Company | $87.81 | 2022 | |
| Dexcom, INC. | $81.24 | 2024-2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $80.78 | 2023-2024 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $78.63 | 2022-2025 | Breztri, Wainua, Farxiga |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $68.70 | 2023-2024 | Austedo Xr |
| Emd Serono, INC. | $63.14 | 2024-2025 | |
| Lundbeck LLC | $57.19 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.51 | 2021-2024 | Jardiance |
| Bausch Health US, LLC | $50.56 | 2022-2023 | Aplenzin |
| Cleerly, INC. | $42.88 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Novartis Pharmaceuticals Corporation | $32.61 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $27.24 | 2024 | |
| Janssen Pharmaceuticals, INC | $25.52 | 2023 | Xarelto |
| Edwards Lifesciences Corporation | $24.37 | 2024 | Sapien 3 Ultra Resilia |
| Exact Sciences Corporation | $18.73 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $16.87 | 2025 | Zoryve |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Savant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.